BMS10 Nov 2020 19:02
Deucravacitinib (BMS-986165) is an orally available, selective inhibitor for the tyrosine kinase 2 (TYK2). The TKY2 protein is responsible for the induction of molecules crucial for inflammatory and immune responses. This drug’s efficacy is currently being evaluated in the POETYK PSO-1 clinical trial, which is a multicenter, randomized, double-blind, placebo- and active comparator-controlled trial.
The trial includes approximately 600 patients, and the full evaluation of the results is still underway. However, preliminary results show that Deucravacitinib treatment was more effective in reducing the psoriasis area by 75% or more and achieving an sPGA score of clear or almost clear when compared to placebo control. Additionally, at Week 16 of the study, more patients reached PSAI 75 and sPGA while taking Deucravacitinib than Otezla. However, more detailed information on the number of patients and the extent of the difference will be available in the first quarter of 2021.
Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, Bristol Myers Squibb, said, “We are encouraged by the efficacy and the safety profile observed in the POETYK PSO-1 study, which supports the strong potential we see for Deucravacitinib, our novel, oral, selective TYK2 inhibitor, to be an important new therapy in psoriasis,” He added, “We recognize there is a significant unmet need for new therapeutic options for people with immune-mediated diseases, such as psoriasis, and are committed to pursuing potential new medicines that will give physicians additional choices to effectively treat and manage their patients.”
Sign In
Follow the stocks
